Compare CLWT & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLWT | PDSB |
|---|---|---|
| Founded | 1971 | 2005 |
| Country | Hong Kong | United States |
| Employees | N/A | 10 |
| Industry | Professional and commerical equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 11.4M |
| IPO Year | 1996 | 2015 |
| Metric | CLWT | PDSB |
|---|---|---|
| Price | $1.71 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 16.9K | ★ 2.9M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $0.20 |
| 52 Week High | $2.68 | $1.55 |
| Indicator | CLWT | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 57.32 | 41.43 |
| Support Level | $1.08 | $0.20 |
| Resistance Level | $1.73 | $0.77 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 70.05 | 21.72 |
Euro Tech Holdings Co Ltd is mainly a distributor of a wide range of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies, and power generation equipment, including recorders and power quality analyzers. The Company acts as an exclusive or non-exclusive distributor for manufacturers of such equipment to commercial customers and governmental agencies in Hong Kong and mainland China, as well as commercial customers in Macau. It has two operating segments: Trading and manufacturing, which generate maximum revenue and act as a distributor of water treatment equipment, laboratory instruments, analyzers, test kits, related supplies, and power generation equipment; and the Engineering segment. The Company generates maximum revenue from the PRC.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.